Search Results - robert+prins

5 Results

Sort By:

Interferon Activation Score Is a Biomarker for Immunotherapy in Malignant Glioma Patients (UCLA Case No. 2024-043)

UCLA researchers from the Department of Neurosurgery have characterized immune responses in malignant glioma patients receiving immunotherapy to develop a robust biomarker that will allow prediction of clinical outcomes following treatment. BACKGROUND: Malignant gliomas are the most common primary brain tumors in adults. No cures exist and most gliomas...

Published: 10/23/2024 | Inventor(s): Robert Prins

Keywords(s): adjuvant therapy, Biomarker, Chemotherapy, Clinical Trial, dendritic cell vaccination, Glioblastoma, Glioma, immune response, Immunotherapy, interferon, malignant glioma

Category(s): Diagnostic Markers > Immunology, Diagnostic Markers > Cancer, Therapeutics > Inflammation And Inflammatory Diseases, Therapeutics > Oncology, Therapeutics > CNS and Neurology

Identification of a Platform to Identify Tumor-Specific T Cell Receptors (UCLA Case No. 2022-082)

SUMMARY: Researchers from UCLA’s Department of Neurosurgery and Pharmacology have developed a rapid discovery platform for the identification of tumor-specific T cell receptors to aid in more personalized and potent immunotherapy for glioblastoma. BACKGROUND: Over the past several years, immunotherapy, or therapies that enlist and strengthen...

Published: 5/20/2024 | Inventor(s): Robert Prins, Alexander Lee, Lu Sun, David Nathanson

Keywords(s):

Category(s): Therapeutics, Therapeutics > CNS and Neurology, Therapeutics > Oncology, Therapeutics > Immunology And Immunotherapy, Therapeutics > Oncology > Oncology Immunotherapy

Targeted Neoantigen Vaccination in H3G34R/V Glioma (UCLA Case No. 2021-008)

UCLA researchers in the Departments of Neurosurgery and Microbiology, Immunology, and Molecular Genetics have developed an immunotherapy treatment methodology for H3G34R/V high-grade glioma, providing an ability to be adapted toward a wide range of similar tumors.BACKGROUND:Over 3000 gliomas and other forms of brain cancer are diagnosed in children...

Published: 5/4/2024 | Inventor(s): Anthony Wang, Geoffrey Owens, Yi Xing, Robert Prins, Linda Liau, David Nathanson

Keywords(s): Immunotherapy, Oncology, Oncology Immunotherapy

Category(s): Therapeutics > Immunology And Immunotherapy, Therapeutics > Oncology, Therapeutics > Oncology > Oncology Immunotherapy

2015-341 COMBINATIONS OF CHECKPOINT INHIBITORS AND DENDRITIC CELL VACCINES TO TREAT BRAIN CANCER

UCLA researchers in the Departments of Neurosurgery and Molecular and Medical Pharmacology have developed an autologous dendritic cell (DC) vaccine in combination with checkpoint inhibitors for the treatment of malignant brain tumors.BACKGROUND: Checkpoint inhibitor therapies, which unblock an existing immune response, or unblock the initiation of an...

Published: 7/19/2023 | Inventor(s): Robert Prins, Linda Liau

Keywords(s): Antibodies, Drug Delivery, Immunotherapy, Oncology, Oncology (Small Molecules, Peptides and Antibodies), Oncology Immunotherapy, Therapeutics & Vaccines, Vaccines

Category(s): Therapeutics > CNS and Neurology, Therapeutics > Vaccines, Therapeutics > Oncology, Therapeutics > Immunology And Immunotherapy, Therapeutics > Oncology > Oncology Immunotherapy, Therapeutics > Oncology > Oncology (Small Molecules)

Identification of a Platform for T Cell Receptor Recognition of Splice Variation Neoantigens in Glioblastoma (UCLA Case No. 2019-693)

UCLA researchers in the Departments of Neurosurgery and Pharmacology have developed a novel platform for the identification of alternative splice variants unique to cancer cells, for use as neo-epitope vaccines or as T cell Receptor-based cell therapy of brain cancer. BACKGROUND:T cells are a type of lymphocyte that play a central role in immune response...

Published: 5/20/2024 | Inventor(s): Robert Prins, Yi Xing

Keywords(s): Diagnostic Markers & Platforms, Oncology, Therapeutics & Vaccines

Category(s): Diagnostic Markers, Therapeutics, Therapeutics > Oncology > Oncology Immunotherapy